Is adjuvant chemotherapy necessary for early gastric cancer?

ABSTRACT:

Objective

To quantify the potential benefit of adjuvant chemotherapy (ACT) with respect to survival, and to identify factors for predicting prognoses in early gastric cancer patients.

Methods

Patients with pT1 gastric cancer (GC) who underwent radical resection with D2 lymphadenectomy were retrospectively analyzed. Based on lymph node metastasis (LNM) status and treatment regimens, patients were classified into groups, and clinicopathological variables, overall survival (OS), and disease-specific survival (DSS) were compared.

Results

Of 1,050 enrolled patients, 151 patients (14.4%) had a positive LNM status. Submucosal invasion, undifferentiated state, tumor size > 2 cm, ulceration, and lymphovascular invasion were independent risk factors for LNM using multivariate a

SUBMITTER: Mei Y 

PROVIDER: S-EPMC9088187 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature